FY2027 EPS Estimates for Arvinas Lowered by Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Leerink Partnrs decreased their FY2027 earnings per share estimates for Arvinas in a report released on Monday, February 3rd. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of $1.08 for the year, down from their prior estimate of $1.38. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share.

Several other equities analysts have also commented on the company. Barclays lowered their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. HC Wainwright restated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. BTIG Research assumed coverage on Arvinas in a research note on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price on the stock. Stephens assumed coverage on shares of Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target for the company. Finally, Oppenheimer cut their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.45.

Arvinas Stock Down 2.1 %

NASDAQ ARVN opened at $18.70 on Thursday. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The business has a 50 day moving average price of $19.75 and a two-hundred day moving average price of $23.67. The stock has a market cap of $1.28 billion, a PE ratio of -4.00 and a beta of 1.88.

Institutional Investors Weigh In On Arvinas

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of Arvinas by 7.6% during the 3rd quarter. FMR LLC now owns 2,883,604 shares of the company’s stock valued at $71,023,000 after purchasing an additional 204,317 shares during the period. JPMorgan Chase & Co. grew its holdings in Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after acquiring an additional 367,343 shares during the period. Braidwell LP raised its position in Arvinas by 148.3% in the third quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock worth $31,637,000 after acquiring an additional 767,242 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its holdings in Arvinas by 1.4% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,244,450 shares of the company’s stock valued at $30,651,000 after acquiring an additional 17,723 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Arvinas by 1.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 536,112 shares of the company’s stock valued at $10,277,000 after purchasing an additional 5,443 shares in the last quarter. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.